Literature DB >> 17692530

Pathophysiology and types of dyslipidemia in PCOS.

Evanthia Diamanti-Kandarakis1, Athanasios G Papavassiliou, Stylianos A Kandarakis, George P Chrousos.   

Abstract

Polycystic ovary syndrome (PCOS) is an endocrinopathy that affects women of reproductive age. PCOS shares components with the metabolic syndrome and has broad health implications. Lipid abnormalities, including elevated low-density lipoprotein (LDL), triglyceride levels and decreased high-density lipoprotein (HDL), are often found in women with PCOS. It is clear that obesity, insulin resistance and hyperandrogenism coexist in PCOS, and have independent and interactive effects on dyslipidemia, although the mechanisms of these interactions remain elusive. Here, we review the types and pathophysiology of dyslipidemia associated with PCOS and its related conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692530     DOI: 10.1016/j.tem.2007.07.004

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  61 in total

1.  Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance.

Authors:  Danalea V Skarra; Angelina Hernández-Carretero; Alissa J Rivera; Arya R Anvar; Varykina G Thackray
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

2.  Association of serum betatrophin with fibroblast growth factor-21 in women with polycystic ovary syndrome.

Authors:  S Kahraman; A E Altinova; M M Yalcin; O Gulbahar; B Arslan; M Akturk; N Cakir; F B Toruner
Journal:  J Endocrinol Invest       Date:  2018-01-23       Impact factor: 4.256

3.  Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis.

Authors:  Shan Li; Xiamei Huang; Huizhi Zhong; Qiliu Peng; Siyuan Chen; Yantong Xie; Xue Qin; Aiping Qin
Journal:  Tumour Biol       Date:  2014-01-12

4.  The effects of old, new and emerging medicines on metabolic aberrations in PCOS.

Authors:  Alexandra Bargiota; Evanthia Diamanti-Kandarakis
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

5.  Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women.

Authors:  Carolyn J Alexander; Edward P Tangchitnob; Norman E Lepor
Journal:  Rev Obstet Gynecol       Date:  2009

6.  Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome.

Authors:  Thomas S Paterakis; Evanthia Diamanti-Kandarakis
Journal:  Curr Obes Rep       Date:  2014-12

Review 7.  Cardiovascular risk factors and events in women with androgen excess.

Authors:  D Macut; I B Antić; J Bjekić-Macut
Journal:  J Endocrinol Invest       Date:  2014-11-29       Impact factor: 4.256

8.  Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women.

Authors:  Daniel A Dumesic; Alin L Akopians; Vanessa K Madrigal; Emmanuel Ramirez; Daniel J Margolis; Manoj K Sarma; Albert M Thomas; Tristan R Grogan; Rasha Haykal; Tery A Schooler; Bette L Okeya; David H Abbott; Gregorio D Chazenbalk
Journal:  J Clin Endocrinol Metab       Date:  2016-08-29       Impact factor: 5.958

9.  Pregnancy Protects Hyperandrogenemic Female Rats From Postmenopausal Hypertension.

Authors:  Noha M Shawky; Chetan N Patil; Carolina Dalmasso; Rodrigo O Maranon; Damian G Romero; Heather Drummond; Jane F Reckelhoff
Journal:  Hypertension       Date:  2020-08-03       Impact factor: 10.190

10.  Cardiometabolic health among gastric bypass surgery patients with polycystic ovarian syndrome.

Authors:  Carley A Gomez-Meade; Gabriela Lopez-Mitnik; Sarah E Messiah; Kristopher L Arheart; Adriana Carrillo; Nestor de la Cruz-Muñoz
Journal:  World J Diabetes       Date:  2013-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.